Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting [Yahoo! Finance]
Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting
Editas Medicine, Inc. (NASDAQ: EDIT) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Editas Medicine, Inc. (NASDAQ:EDIT) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
Editas Medicine, Inc. (NASDAQ: EDIT) had its price target lowered by analysts at Citigroup Inc. from $16.00 to $15.00. They now have a "buy" rating on the stock.